Germany Pharmaceutical CDMO Market Size was valued at USD 14.2 Billion in 2022. The Pharmaceutical CDMO Market industry is projected to grow from USD 15.1 Billion in 2023 to USD 26.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.00% during the forecast period (2024 - 2032). The rising complexity and cost of drug development and manufacturing processes and the growing focus on research and development of innovative therapies are the main market drivers anticipated to propel the Pharmaceutical CDMO Market in Germany.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
One of the primary factors driving the growth of the Pharmaceutical CDMO Market CAGR is the increase in chronic disease treatment. The contract development and manufacturing department is responsible for drug research and manufacturing, as well as technology advances in the pharmaceutical business. The rising frequency of chronic diseases in the population will result in a greater demand for improved and effective therapy in order to cure individuals faster and more effectively. The rise in chronic disorders such as cancer is propelling the market. Cancer is the leading cause of death over the last several decades. The expanding need for treatment advancement, as well as the growing demand for cancer therapy, will drive the pharmaceutical and contract development and manufacturing organization market. In addition, the increase in generic and tailored pharmaceuticals will benefit the contract development and manufacturing organization market. A technological breakthrough in the healthcare industry completed drug formulation. Increasing collaboration among pharmaceutical firms, rising R&D investments, and an increase in the elderly population will all contribute to stronger market growth in the pharmaceutical CDMO industry.
Moreover, pharmaceutical contract development and manufacturing organizations (CDMOs) use cutting-edge operating technologies. The rise in demand for precision medicine and generics will create new growth prospects in the contract development and manufacturing organization industry. Technological breakthroughs such as the deployment of artificial intelligence, blockchain, cloud computing, and machine learning are likely to provide profitable prospects for market growth over the research period. The pharmaceutical CDMO is setting targets for technological leadership, which is expected to rise in the future decades. The increasing mergers and acquisitions in contract development and manufacturing organizations will drive market expansion.
The Germany Pharmaceutical CDMO Market segmentation, based on product type, includes Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, and Secondary Packaging. The Active Pharmaceutical Ingredient (API) Manufacturing segment had the highest market revenue in the contract development and manufacturing organization market in 2023, and it will continue to grow at a rapid pace during the forecast period. The API (Active Pharmaceutical Ingredients) is the first form of the finished drug product. The contract development and manufacturing organization made a significant investment in the APIs market due to increased demand in the segment. The API is effective in the diagnosis, treatment, and prevention of disorders affecting the human body. The API specifies the type of medicine, such as novel and generic drugs.
The Germany Pharmaceutical CDMO Market segmentation, based on applications, includes Small & Mid-Size Pharma Companies, Generic Pharmaceutical Companies and Big Pharma Companies. In 2023, the Big Pharma Companies will dominate the contract development and manufacturing organization market. The large pharmaceutical industries have made the majority of their investments in the Pharmaceutical CDMO sector and can invest in medication discovery and manufacturing. Outsourcing and manufacturing pharmaceuticals to CDMOs will lower the cost of the drug and allow the large pharmaceutical sector to compete in the market.
Figure 1: Germany Pharmaceutical CDMO Market, Applications, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Germany is predicted to make the highest contribution to market growth. Furthermore, the Pharmaceutical CDMO (Contract Development and Manufacturing Organization) Market is expanding rapidly globally. CDMOs offer a variety of services to pharmaceutical businesses, such as medication development, manufacturing, and packaging. This market is being pushed by a number of factors, including the increasing complexity and cost of drug development, the expanding emphasis on research and development of new therapeutics, and the need for specialized skills and capabilities within the pharmaceutical sector.
Germany Pharmaceutical CDMO Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Pharmaceutical CDMO Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Pharmaceutical CDMO industry must offer cost-effective items.
Major players in the Pharmaceutical CDMO Market are attempting to increase market demand by investing in research and development operations, including SGS Life Science Services SA, Novotech Pty Ltd, Syneos Health Inc., Hangzhou Tigermed Consulting Co. Ltd, IQVIA Holdings Inc., Samsung Bioepis Co. Ltd, CMIC Holdings Co. Ltd, LSK Global Pharma Service Co. Ltd, PRA Health Sciences Inc., Covance Inc., PAREXEL International Corporation, Quanticate Ltd, WuXi AppTec Inc., Pharmaceutical Product Development LLC, Sagimet Biosciences (3V Biosciences Inc.).
Key Companies in the Pharmaceutical CDMO Market include
Germany Pharmaceutical CDMO Industry Developments
In March 2022, Acanthus Research Inc., which provides high-end reference standards and organic synthesis services, launched Acanthus Pharma solution, a CMDO solution for pharmaceutical and biotech services.
In October 2022, Medipost announced the establishment of a new CDMO company for cell and gene therapy products in the Korean market. Medipost intends to launch such services as a one-stop solution for the development of pharmaceutical and biopharmaceutical goods.
In April 2023, The Bridgewest Group, a global private investment firm that deals with life science software and contract development and manufacturing organizations, created a new Sterile injectables CDMO, NovaCina. NovaCina turns the product into a full-scale commercial product.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 14.2 Billion |
| Market Size 2023 | USD 15.1 Billion |
| Market Size 2032 | USD 26.1 Billion |
| Compound Annual Growth Rate (CAGR) | 7.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Application, and Region |
| Countries Covered | Germany |
| Key Companies Profiled | SGS Life Science Services SA, Novotech Pty Ltd, Syneos Health Inc., Hangzhou Tigermed Consulting Co. Ltd, IQVIA Holdings Inc., Samsung Bioepis Co. Ltd, CMIC Holdings Co. Ltd, LSK Global Pharma Service Co. Ltd, PRA Health Sciences Inc., Covance Inc., PAREXEL International Corporation, Quanticate Ltd, WuXi AppTec Inc., Pharmaceutical Product Development LLC, Sagimet Biosciences (3V Biosciences Inc.). |
| Key Market Opportunities | Expansion of CDMO services in emerging markets. |
| Key Market Dynamics | Increasing demand for personalized medicine and biologics. |
Frequently Asked Questions (FAQ) :
The Germany Pharmaceutical CDMO Market size was valued at USD 15.1 Billion in 2023.
The market is projected to grow at a CAGR of 7.00% during the forecast period, 2024-2032.
The key players in the market are SGS Life Science Services SA, Novotech Pty Ltd, Syneos Health Inc., Hangzhou Tigermed Consulting Co. Ltd, IQVIA Holdings Inc., Samsung Bioepis Co. Ltd, CMIC Holdings Co. Ltd, LSK Global Pharma Service Co. Ltd, PRA Health Sciences Inc. And others.
The Active Pharmaceutical Ingredient (API) Manufacturing category dominated the market in 2023.
The Big Pharma Companies had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
